Safety profile of levetiracetam

Epilepsia

Volumn 42, Issue SUPPL. 4, 2001, Pages 36-39

  Harden, C ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Adverse event; Antiepileptic drugs; Levetiracetam; Safety profile; Tolerability

Indexed keywords

ETIRACETAM;

ADULT; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SOMNOLENCE; VERTIGO;

EID: 0034878396     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2001.00008.x     Document Type: Review

References (9)

1. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
2. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
3. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy
4. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
5. Levetiracetam: Serious adverse experiences and SUDEP
6. Long-term continuation of levetiracetam in patients with refractory epilepsy